| GNNSF Stock | | | USD 1.37 0.00 0.00% |
President
Mr. Meng Jiange is Vice President Investor Relations, Executive Director of the company. Since August 24, 2015 and is primarily responsible for our Companys finance matters. He was appointed as the vice president of finance of our Group in April 2010 when he joined our Group. Mr. Meng has over 25 years of experience in finance and accounting. Prior to joining our Group, from July 1990 to October 1997, Mr. Meng worked at CCCC Guangzhou Dredging Co., Ltd. From January 1999 to May 2000, Mr. Meng worked as the national finance manager at Guangdong Whirlpool Home Appliance Group. From May 2000 to July 2004, Mr. Meng worked at ScheringPlough China as a branch finance manager and the accounting and IT manager in the head office. From September 2004 to December 2007, Mr. Meng worked as the Asia finance controller of SaintGobain Grains and Powder Division. From March 2008 to March 2010, Mr. Meng worked as the chief financial officer of Quay Magnesium since 2015.
| Age | 55 |
| Tenure | 9 years |
| Phone | 86 25 5889 7288 |
| Web | https://www.genscript.com |
Meng graduated from Changsha Communications Institute (currently known as Changsha University of Science Technology in the PRC with a Bachelor of Engineering degree in July 1990.
Genscript Biotech Management Efficiency
The company has return on total asset
(ROA) of
(0.1165) % which means that it has lost $0.1165 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.5574) %, meaning that it generated substantial loss on money invested by shareholders. Genscript Biotech's management efficiency ratios could be used to measure how well Genscript Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
Genscript Biotech has accumulated 121.07
M in total debt with debt to equity ratio
(D/E) of 0.56, which is about average as compared to similar companies. Genscript Biotech has a current ratio of 2.86, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Genscript Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Genscript Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Genscript Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Genscript to invest in growth at high rates of return. When we think about Genscript Biotech's use of debt, we should always consider it together with cash and equity.
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the Peoples Republic of China, Japan, the other Asia Pacific regions, and internationally. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the Peoples Republic of China. Genscript Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5573 people. Genscript Biotech [GNNSF] is a
Pink Sheet which is traded through a dealer network over-the-counter (OTC).
Management Performance
Genscript Biotech Leadership Team
Elected by the shareholders, the Genscript Biotech's board of directors comprises two types of representatives: Genscript Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genscript. The board's role is to monitor Genscript Biotech's management team and ensure that shareholders' interests are well served. Genscript Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genscript Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shiniu Wei, Chief Officer | |
| Li Zhu, Vice President - Strategy | |
| Brian Min, CEO Bus | |
| Zhenyu Liu, Chief Officer | |
| Jiange Meng, Vice President - Finance, Executive Director | |
| Weihui Shao, Chief Officer | |
| Chifa Zhang, Department head - industry synthetic biology product segment | |
| ACIS ACS, Company Sec | |
| Ye MS, Pres CoFounder | |
| ChuanChu Chou, Department head - Preclinical Drug Development Service Business Segment | |
Genscript Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Genscript Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Genscript Pink Sheet
Genscript Biotech financial ratios help investors to determine whether Genscript Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genscript with respect to the benefits of owning Genscript Biotech security.